Inke attends the Inhalation and Respiratory Drug Delivery conference in Barcelona

During 2023, Inke has increased its production capacity by making a significant investment in new reactors and clean rooms. This initiative has been carried out with the support of ACCIÓ from the Generalitat de Catalunya.

Transaction enables Neuraxpharm to further focus on its core CNS therapeutic area and for Inke to accelerate its development as an independent entity.